Abstract
Background The acetabular pathomorphology in patients with Crowe type II and III developmental dysplasia of the hip(DDH)often present complicated changes, which bring challenges to the anatomical reconstruction of acetabulum in total hip arthroplasty (THA). The objective of this study was to develope a novel 3D printed integral customized acetabular prosthesis, which provides a promising way to reconstruct the acetabulum with higher accuracy and efficiency by digital softwares, compared with previous 3D printing model method.
Methods 15 patients (18 hips) with end-stage hip osteoarthritis due to Crowe type II/III DDH who underwent primary cementless THA from January 2015 to November 2021 were included. The 15 patients consisted of 3 men (3 hips) and 12 women (15 hips) with an average age of 53.89 ± 8.48 years (range from 32 to 69 years). The novel 3D printed integral customized acetabular prosthesis was designed by the model method and software method respectively. The indicators of the cup size, the volume and superficial area of bone defect, the inclination and anteversion of acetabular cup, the horizontal and vertical distance of hip center and working time were compared between two methods.
Results There were statistically significant difference between the software group and model group on the volume and superficial area of bone defect as well as working time (t = 2.397, 2.707,138.509, P < 0.05). The mean anteversion and inclination of acetabular cup in the software group and model group were(15.17±0.52)°,(40.24±0.58)°and (33.79 ±13.43)°, (30.50 ±11.03)°respectively, the difference was statistically significant (t = 5.859, 3.767, P < 0.05).There were no statistically significant difference between the software group and model group on cup size, the horizontal and vertical distance of hip center(t =1.458,0.114, 1.712, P > 0.05)
Conclusions The application of digital softwares could design and develope the novel 3D printed integral customized anatomical acetabular prosthesis in THA for □Crowe type II and III DDH with high accuracy and efficiency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The full name of each funder
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee on Human Research of the First Affiliated Hospital of Bengbu Medical College (2011053), and informed written consent was obtained from all involved patients
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* the first author
Data Availability
The data underlying the results presented in the study